Genmab Up 28%, Axogen Up 31% on Oct 28, 2026: Which Rally Has a Filing Behind It

Basis: Oct 29, 2026, 08:45 KST. Market basis: Oct 28 (U.S.) close.

Seoul — U.S. stocks rose about 0.3% on Oct 28, but three names jumped 17% to 31%. The cause is documented for Axogen (AXGN), which filed an 8-K (a report of major events) with its Q3 results. For Genmab (GMAB), which reported Phase 3 trial results, and ICON (ICLR), which reported earnings, the reasons come from news headlines only, since the 6-Ks (the report foreign companies file with the SEC) filed around the move have no item codes or text to read.

Key points

• The S&P 500 closed at 7,743.98 (+0.28%), the Nasdaq Composite at 26,549.85 (+0.27%) and the small-cap Russell 2000 at 2,830.51 (+0.41%).
• Axogen rose 31.47%, Genmab 28.25% and ICON 17.04%.
• Dollar volume was about $1.67 billion for Genmab, $845 million for ICON and $457 million for Axogen.
• Overheating signals: Genmab 4/4, Axogen 3/4, ICON 1/4.

At a glance

Axogen jumped 31% on Q3 results and a higher revenue outlook

Axogen rose 31.47% to close at $49.25 on the day it reported third-quarter results, and the release is confirmed by an 8-K. The company's Oct 28 8-K (items 2.02, 7.01, 9.01) furnished the Q3 earnings press release as Exhibit 99.1 and said it posted an earnings presentation and a corporate presentation on its website. A 10-Q was filed the same day. We class the filing as positive. The guidance raise to at least $290 million in 2026 revenue comes from a TIKR.com headline, and the 8-K text we could read does not show that figure.

The results were not all good news. Stock Titan's headline says Q3 profit was $2.33 million but the nine-month loss widened. Timothy Sykes and StocksToTrade cited a 'BioCircuit deal' in their headlines, but no such deal can be confirmed in the company's 8-K. The stock fell 20% from $43.32 on Sept 24 to $34.62 on Oct 16 and is now 13.7% above the Sept 24 close.

On overheating, 3 of 4 signals are on: RSI of 82.1, a price 32.2% above its 20-day average and volume 6.0 times normal. Dollar volume of $457 million was almost 16% of the roughly $2.89 billion market value. The stock sits at 92% of its 52-week range, 4.8% below the high and 25.1% above its 200-day average. It passes 3 of 6 fundamentals checks, with revenue growth of 23.1%.

Two things show whether this holds. One is whether the company itself confirms the reported BioCircuit deal in an 8-K or press release. The other is whether the 10-Q's nine-month results and cash flow show the profit was more than a single quarter.

Genmab rose 28% on Phase 3 trial reports and hit a new 52-week high

Genmab rose 28.25% to $57.29 as Phase 3 trial results came out. Yahoo Finance said three positive Phase 3 readouts set the stage for potential 2027 cancer launches, and TipRanks reported a gain of more than 30% intraday on strong Phase 3 results for a head and neck cancer treatment. Timothy Sykes pointed to Rina-S and Petosemtamab data. The trial results are already out, so the news is substantive, but much of the price now rests on future approvals and launches.

The SEC filings are two 6-Ks, dated Oct 28 and Oct 23, with no item codes and no text we could read, so the trial figures are not confirmed by a filing. When we covered Genmab on Oct 24 and labeled it 'news only', it had closed at $43.79; it has since risen 30.8%. Market value grew by about $7.8 billion in one day to roughly $35.2 billion.

Overheating shows 4 of 4 signals: RSI of 93.3, a price 45.3% above its 20-day average, volume 5.6 times normal and a 44.8% gain over five days. The stock is at its 52-week high and 89.2% above its 200-day average. It passes 5 of 6 fundamentals checks, though its P/E is 45.1.

Two things to check: whether the Oct 28 6-K contains the trial figures and regulatory timelines, and whether dollar volume, above $1.6 billion on the day, holds up the next session.

ICON rose 17% after earnings (a 6-K exists, but figures come from news only)

ICON rose 17.04% to $214.16 after its third-quarter report. Timothy Sykes headlines said an earnings beat and higher guidance drove the stock, and that guidance and backlog impressed Wall Street. The earnings call took place the morning of Oct 28, according to Seeking Alpha and Benzinga headlines.

Two 6-Ks were filed on Oct 27, and one has a file name that reads as Q3 results, but with no item codes or text the actual figures rest on headlines. A Form 4 (insider transaction report) was also filed on Oct 26, and its contents are unknown. Revenue growth is only 1.2% and the P/E is 225.4, so the size of the move is large relative to the company's growth.

Overheating shows 1 of 4 signals, labeled 'caution'. RSI of 85.8 is past the threshold, while the price is 23.5% above its 20-day average, volume is 4.6 times normal and the five-day gain is 15.6%, all below the thresholds. The stock is at its 52-week high, 47.2% above its 200-day average, and passes 4 of 6 fundamentals checks.

To judge whether the gain lasts, compare the full-year guidance figure in the 6-K with what the headlines say, and watch whether backlog turns into faster revenue growth in later quarters.

Stocks we covered earlier, and what happened next

Here are the eight stocks from earlier articles, with the label we gave them and their move to the Oct 28 close. Results differed by label.

The three 'filing' names split at +5.7%, -8.7% and -10.5%, and the three 'no reason' names at +9.2%, +9.1% and -10.9%, so the label did not predict direction. The biggest gainer was Genmab, labeled 'news', whose rise continued into Oct 28's Phase 3 reports.